ESC 365 - When will be appropriate time for P2Y12 inhibitors dose de-escalation?

ESC Premium Access

When will be appropriate time for P2Y12 inhibitors dose de-escalation?

Session: Poster Session 2 - Coronary artery disease: pharmacotherapy

Topic: Pharmacotherapy

Speaker: Mr M. Chung (Busan, KR)

Event: ESC Congress 2018

Congress Presentation

Add to my library

About the speaker

Mr Matthew Chung

Busan (Korea (Republic of))

0 follower

9 more presentations in this session

Risk stratification for ischemic and bleeding events in patients using a potent P2Y12 inhibitor

Speaker: Doctor Y. Park (Changwon, KR)

Clinical effects of beta blocker selectivity and dosage regimens in acute myocardial infarction: propensity-score matching analysis

Speaker: Professor U. Kim (Daegu, KR)

Three for two - a meta-analysis on the optimal antithrombotic regimen in patients undergoing coronary stent implantation with an indication to anticoagulation therapy

Speaker: Doctor F. Fortuni (Perugia, IT)

Patients eligible for prolonged dual antiplatelet treatment one year after acute coronary syndrome according to the of PRECISE-DAPT score and DAPT score

Speaker: Doctor A. Cordero (Elche, ES)

Single agent clopidogrel is associated with increased all cause mortality compared with aspirin only treatment.

Speaker: Mr V. Parmar (Bushey, GB)

Access the full session

Poster Session 2 - Coronary artery disease: pharmacotherapy

Speakers: Mr M. Chung, Doctor Y. Park, Professor U. Kim, Doctor F. Fortuni, Doctor A. Cordero...

About the event

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources